• 1
    Sotelo J, Jung H. Pharmacokinetics optimisation of the treatment of neurocysticercosis. Clin Pharmacokin 1998; 34: 503515.
  • 2
    Takayanagui OM, Jardim E. Therapy for neurocysticercosis. Arch Neurol 1992; 49: 290294.
  • 3
    Benoit E, Besse S, Delatour P. Effect of repeated doses of albendazole on enantiomerism of its sulfoxide metabolite in goats. Am J Vet Res 1992; 53: 16631665.
  • 4
    Delatour P, Benoit E, Besse S, Boukraa A. Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs and rats. Xenobiotica 1991; 21: 217221.
  • 5
    Delatour P, Benoit E, Caude M, Tambute A. Species differences in the generation of the chiral sulfoxide metabolite of albendazole in sheep and rats. Chirality 1990; 2: 156160.
  • 6
    Delatour P, Garnier F, Benoit E, Caude I. Chiral behaviour of the metabolite albendazole sulphoxide in sheep, goats and cattle. Res Vet Sci 1991; 50: 134138.
  • 7
    Marriner SE, Morris DL, Dickson B, Bogan JA. Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 1986; 30: 705708.
  • 8
    Homeida M, Leahy W, Copeland S, Ali MMM, Harron DWG. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann Trop Med Parasitol 1994; 88: 551559.
  • 9
    Cotting J, Zeugin T, Steiger U, Reichen J. Albendazole kinetics in patients with echinococcosis; delayed absorption and impaired elimination in cholestasis. Eur J Clin Pharmacol 1990; 38: 605608.
  • 10
    Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 1988; 34: 315317.
  • 11
    Steiger U, Cotting J, Reichen J. Albendazole treatment of echinococcosis in humans: effects on microsomal metabolism and drug tolerance. Clin Pharmacol Ther 1990; 47: 347353.
  • 12
    Jung H, Hurtado M, Medina MT, Sanchez M, Sotelo J. Dexamethasone increases plasma levels of albendazole. J Neurol 1990; 231: 279280.
  • 13
    Jung H, Hurtado M, Sanchez M, Medina MT, Sotelo J. Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. J Clin Pharmacol 1992; 32: 2831.
  • 14
    Marques MP, Takayanagui OM, Bonato PS, Santos SRCJ, Lanchote VL. Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. Chirality 1999; 11: 218223.
  • 15
    Sánches M, Suástegui R, Gonzáles-Esquivel D, Sotelo J, Jung H. Pharmacokinetic comparison of two albendazole dosage regimens in patients with neurocysticercosis. Clin Neuropharmacol 1993; 16: 7782.
  • 16
    Takayanagui OM, Lanchote VL, Marques MPC, Bonato PS. Therapy for neurocysticercosis. pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Ther Drug Monit 1997; 19: 5155.
  • 17
    Rawden HC, Kokwaro GO, Ward SA, Edwards G. Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 2000; 49: 313322.
  • 18
    Souhaili-El Amri H, Mothe O, Totis M, et al. Albendazole sulfonation by rat liver cytochrome P-450c. J Pharmacol Exp Ther 1988; 46: 758764.
  • 19
    Moroni P, Buronfosse T, Longin-Sauvageon C, Delatour P, Benoit E. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monoxygenases from rat liver microsomes. Drug Metab Dispos 1995; 23: 160164.
  • 20
    Lanchote VL, Marques MPC, Takayanagui OM, Carvalho R, Bonato PS. Simultaneous determination of albendazole sulfoxide enantiomers and albendazole sulfone in plasma. J Chromatogr B 1998; 709: 273279.
  • 21
    Proano JV, Madrazo I, Avelar F, Lopez-Felix B, Diaz G, Grijalva I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001; 345: 879885.
  • 22
    Kearney BP, Aweeka FT. The penetration of anti-infectives into the central nervous system. Neurol Clin 1999; 17: 883900.
  • 23
    Fishman RA. Cerebrospinal Fluid in Diseases of the Nervous System, 2nd edn. Saunders, Philadelphia, 1992.